Congress reached an agreement on a $1.3 trillion spending bill that includes a provision allowing gun violence research, but does not include 2 drug pricing measures or a provision to stabilize the Affordable Care Act markets; and FDA has released 2 draft guidances on postmarketing safety reporting requirements.
Congress reached an agreement for a $1.3 trillion federal spending bill that would boost investment in the National Institutes of Health by $3 billion but is also missing some key health measures. The bill left out a provision that would reduce drug companies’ share of costs when beneficiaries reach the Medicare donut hole, as well as the CREATES Act, which would crack down on delay tactics pharmaceutical companies use to prevent competition of cheaper generic drugs. The bill also did not include a fix to stabilize the Affordable Care Act markets.
The funding bill opens the path for public health research into gun violence. Such research by the CDC had been banned under the 1996 legislation known as the “Dickey Amendment,” but the new provision partially alters that ban, according to The Wall Street Journal. The Dickey Amendment was supposed to prevent the CDC from advocating for gun control, but it had been interpreted as a blanket prohibition on gun violence research. The new provision will allow CDC to conduct research on the public health impact of gun use, but still prohibits the agency from advocating for gun control.
The FDA has released new guidelines on extending the postmarketing safety reporting requirements for some combination treatments. FierceBiotech reported that one draft guidance provides clarity on meeting requirements, as well as streamlining opportunities, and the second outlines the compliance policy.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More